CIK 0001061983
- Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 943291317
- Phone
- +1 650-624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,320,469
- in 18 filings, $12.5M under 10b5-1 plans
Net −$13,320,469. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Blum Robert I −$9.7M President & CEO sold 34% of stake
- Malik Fady Ibraham −$1.3M EVP Research & Development sold 12% of stake
- Hessekiel Jeffrey −$795K Chief Legal & Admin Officer sold 14% of stake
- Callos Andrew −$702K EVP, Chief Commercial Officer sold 15% of stake
- PARSHALL B LYNNE −$631K Director sold 63% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-01 | Blum Robert I President & CEO | Sale 10b5-1 | −1,809 | $32.63 | $59K | 441,417 |
| 2023-08-01 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −10,691 | 10,000 | ||
| 2023-08-01 | Blum Robert I President & CEO | Exercise or conversion · Incentive Stock Option (Right to Buy) 10b5-1 | −1,809 | 11,708 | ||
| 2023-07-13 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $9.65 | $121K | 453,917 |
| 2023-07-13 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $35.28 | $441K | 441,417 |
| 2023-07-13 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 20,691 | ||
| 2023-07-13 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,500 | $35.37 | $88K | 160,664 |
| 2023-07-07 | Bhanji Muna Director | Sale 10b5-1 | −2,000 | $34.12 | $68K | 14,031 |
| 2023-07-03 | Wysenski Nancy Director | Grant or award | +187 | $33.36 | $6K | 16,858 |
| 2023-07-03 | WIERENGA WENDALL Director | Grant or award | +374 | $33.36 | $12K | 18,205 |
| 2023-07-03 | SMITH SANDFORD D Director | Grant or award | +374 | $33.36 | $12K | 18,205 |
| 2023-07-03 | Kaye Edward M. MD Director | Grant or award | +374 | $33.36 | $12K | 18,721 |
| 2023-07-03 | HENDERSON JOHN T Director | Grant or award | +636 | $33.36 | $21K | 31,056 |
| 2023-07-03 | Harrington Robert Arthur Director | Grant or award | +374 | $33.36 | $12K | 10,925 |
| 2023-07-03 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $9.65 | $121K | 453,917 |
| 2023-07-03 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $32.60 | $408K | 441,417 |
| 2023-07-03 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 33,191 | ||
| 2023-06-12 | Blum Robert I President & CEO | Exercise or conversion 10b5-1 | +12,500 | $9.65 | $121K | 453,917 |
| 2023-06-12 | Blum Robert I President & CEO | Sale 10b5-1 | −12,500 | $37.06 | $463K | 441,417 |
| 2023-06-12 | Blum Robert I President & CEO | Exercise or conversion · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −12,500 | 45,691 |
Page 40 of 45 · 885 trades